YI logo

111 INC

YINASDAQ
πŸ† #4638 by market capEarnings Nov 26US Equity
$3.50β–Ό $0.14 (βˆ’4.11%)
πŸŒ™ After hours$3.50β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track YI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.1%
7dβ–Ό 2.6%
14dβ–² 0.3%
30dβ–² 10.2%
ytdβ–² 10.1%
1yβ–Ό 22.2%
🏦Market Cap
$31M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-15.2%
Declining
πŸ“ŠGross Margin
5.7%
Thin
πŸ’΅FCF Margin
-0.4%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
76
Good

Trading Snapshot

Day Range
$3.49 – $3.57
52-Week Range
$2.48 – $11.17
Volume
$2.81B
Avg Volume
$2.04B
Shares Outstanding
8.7M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$12.21B
Last Q Revenue
$2.30B
P/E Ratio
-2.0
P/S Ratio
0.0x
EPS (TTM)
$-10.77
Dividend Yield
0.00%
Dilution (1yr)
+1.4%

Why Investors Own YI

  • βœ“High-growth profile β€” revenue up +29.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 57% gross margin and 19% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

YI logo

111 INC

YI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$12.2Bβ–Ό βˆ’15.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
5.8%β–² +0.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$10Mβ–Ό βˆ’574.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$115Mβ–Ό βˆ’53.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.8Mβ–² +1.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$344Mβ–² +$138M YoY
StockOtter Β· stockotter.space

About 111 INC

Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy4
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Jul 2023

Latest News & Updates